Evidence map›Paper›PMID 39829576›Full record

ArticleACS omega2025

Novel Electrochemical Approaches for Anticancer Drug Monitoring: Application of CoS@Nitrogen-Doped Amorphous Porous Carbon Composite in Nilotinib Detection.

Merve Yıldır, Asena Ayse Genc, Nesrin Buğday, Nevin Erk, Naeimeh Sadat Peighambardoust, Umut Aydemir, Sedat Yaşar

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Merve YıldırFaculty of Pharmacy, Department of Analytical Chemistry, Ankara University, 06560 Ankara, Turkey.
Asena Ayse GencFaculty of Pharmacy, Department of Analytical Chemistry, Ankara University, 06560 Ankara, Turkey.
Nesrin BuğdayFaculty of Science and Art, Department of Chemistry, İnönü Üniversity, 44280 Malatya, Turkey.
Nevin ErkFaculty of Pharmacy, Department of Analytical Chemistry, Ankara University, 06560 Ankara, Turkey.ORCID https://orcid.org/0000-0001-5366-9275
Naeimeh Sadat PeighambardoustBoron and Advanced Materials Research Center (KUBAM), Koç University, 34450 Istanbul, Turkey.ORCID https://orcid.org/0000-0002-2991-5488
Umut AydemirBoron and Advanced Materials Research Center (KUBAM), Koç University, 34450 Istanbul, Turkey.ORCID https://orcid.org/0000-0003-1164-1973
Sedat YaşarFaculty of Science and Art, Department of Chemistry, İnönü Üniversity, 44280 Malatya, Turkey.ORCID https://orcid.org/0000-0001-7285-2761

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A novel composite containing CoS and nitrogen-doped amorphous porous carbon (NAPC), denoted as CoS@NAPC, was successfully synthesized from a mixture of cobalt-based ZIF-12 and sulfur through one-pot pyrolysis. The morphology and microstructure of the composites are evaluated with appropriate spectroscopic techniques. CoS@NAPC was used to modify the glassy carbon electrode (GCE) to detect Nilotinib. Under optimized conditions, the GCE electrode modified with CoS@NAPC showed a low limit of detection (LOD) of 11.8 ng/mL and two wide linear concentration ranges of 59.7-1570 and 1570-11200 ng/mL for the determination of Nilotinib. GCE electrode modified with CoS@NAPC has excellent recoveries ranging from 98.41 to 102.03% for real samples, demonstrating its superior analytical performance. The enhanced performance of CoS@NAPC as an electrochemical sensor may stem from the combined action of two key components: CoS, known for its potent reactivity toward Nilotinib, and NAPC, which offers a consistent conductive carbon matrix. CoS contributes to its reactivity, while NAPC facilitates electron transfer during Nilotinib detection. This synergistic effect likely underlies the superior sensor performance observed.

Identifiers

PMID39829576
PMCPMC11740382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.